Oxidative Stress and Neurodegeneration

Abstract: Oxidative stress is a well‐studied early response in chronic neurodegenerative diseases, including Alzheimer's disease, where neuronal loss can exceed 90% in the vulnerable neuronal population. Oxidative stress affects all classes of macromolecules (sugar, lipids, proteins, and DNA), leading inevitably to neuronal dysfunction. We observed that Nε‐(carboxymethyl)lysine (CML), the predominant advanced glycation end product that accumulates in vivo, along with its glycation‐specific precursor hexitol‐lysine, are increased in neurons from cases of Alzheimer's disease, especially those containing intracellular neurofibrillary pathology. The increase in hexitol‐lysine and CML can result from either lipid peroxidation or advanced glycation, whereas hexitol‐lysine is solely a product of glycation, suggesting that two distinct oxidative processes act in concert in the neuropathology of the disease. Furthermore, using olfactory neurons as an experimental model, we observed an increase in glycation products in neurons derived from Alzheimer's disease patients. Our findings support the idea that aldehyde‐mediated modifications, in concert with oxyradical‐mediated modifications, are critical early pathogenic factors in Alzheimer's disease.

[1]  V. Fried,et al.  Immunochemical Properties of Ubiquitin Conjugates in the Paired Helical Filaments of Alzheimer Disease , 1989, Journal of neurochemistry.

[2]  K. Tatsumi,et al.  2‐Isopropylidenehydrazono‐4‐oxo‐thiazolidin‐5‐ylacetanilide (OPB‐9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage , 1999, FEBS letters.

[3]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[4]  P. Riederer,et al.  Alzheimer's disease – synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts , 1998, Journal of Neural Transmission.

[5]  M. Smith,et al.  Advanced glycation modification of Rosenthal fibers in patients with Alexander disease , 1997, Neuroscience Letters.

[6]  R. Castellani,et al.  Active glycation in neurofibrillary pathology of Alzheimer disease: Nε-(Carboxymethyl) lysine and hexitol-lysine , 2001 .

[7]  G. Perry,et al.  Advanced Maillard reaction end products are associated with Alzheimer disease pathology. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Bucala,et al.  Advanced glycation end products contribute to amyloidosis in Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  E. Schleicher,et al.  Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. , 1997, The Journal of clinical investigation.

[10]  B. Friguet,et al.  Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Formation of cross-linked protein that inhibits the multicatalytic protease. , 1994, The Journal of biological chemistry.

[11]  M. Simionescu,et al.  The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. , 1994, The Journal of biological chemistry.

[12]  George Perry,et al.  RNA Oxidation Is a Prominent Feature of Vulnerable Neurons in Alzheimer’s Disease , 1999, The Journal of Neuroscience.

[13]  J. Baynes,et al.  N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. , 1995, Biochemistry.

[14]  Xiongwei Zhu,et al.  Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response. , 2002, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[15]  T. Lyons,et al.  The Advanced Glycation End Product, N-(Carboxymethyl)lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions (*) , 1996, The Journal of Biological Chemistry.

[16]  R. Fariello,et al.  The prepiriform cortex in dementia of the Alzheimer type. , 1987, Archives of neurology.

[17]  A. Nunomura,et al.  Oxidative Damage Is the Earliest Event in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[18]  G K Wilcock,et al.  Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Smith,et al.  Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease , 1996, Brain Research.

[20]  R. Bucala,et al.  Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[21]  J. Ávila,et al.  Analysis of microtubule-associated protein tau glycation in paired helical filaments. , 1994, The Journal of biological chemistry.

[22]  J. Thome,et al.  Advanced glycation endproducts-associated parameters in the peripheral blood of patients with Alzheimer's disease. , 1996, Life sciences.

[23]  J. Thome,et al.  Advanced glycation endproducts in ageing and Alzheimer's disease , 1997, Brain Research Reviews.

[24]  G. Siest,et al.  Increased protein glycation in cerebrospinal fluid of Alzheimer’s disease 2 2 Abbreviations: AD, Alzheimer’s disease; AGEs, advanced glycation end products; apo, apolipoprotein; BSA, bovine serum albumin; CSF, cerebrospinal fluid; ELISA, enzyme-linked immunosorbent assay; PBS, phosphate buffe , 2001, Neurobiology of Aging.

[25]  Mark A. Smith,et al.  4‐Hydroxynonenal‐Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease , 1997, Journal of neurochemistry.

[26]  G. Perry,et al.  Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. , 1994, The American journal of pathology.

[27]  M. Tabaton,et al.  Abnormal tau‐reactive filaments in olfactory mucosa in biopsy specimens of patients with probable Alzheimer's disease , 1991, Neurology.

[28]  J. Eyer,et al.  Progressive hyperphosphorylation of neurofilament heavy subunits with aging: possible involvement in the mechanism of neurofilament accumulation. , 1995, Biochemical and biophysical research communications.

[29]  T. Lyons,et al.  Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen. , 1991, Biochemistry.

[30]  George Perry,et al.  Oxidative stress signalling in Alzheimer's disease , 2004, Brain Research.

[31]  T. Montine,et al.  E-4-hydroxy-2-nonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures. , 1996, The American journal of pathology.

[32]  T. Kodama,et al.  Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. , 1995, The American journal of pathology.

[33]  G. Perry,et al.  Oxidative damage in the olfactory system in Alzheimer's disease , 2003, Acta Neuropathologica.

[34]  S. Yen,et al.  An immunochemical study on tau glycation in paired helical filaments , 1999, Brain Research.

[35]  R. Castellani,et al.  Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease. , 1998, Journal of Alzheimer's disease : JAD.

[36]  J Q Trojanowski,et al.  Human olfactory epithelium in normal aging, alzheimer's disease, and other neurodegenerative disorders , 1991, The Journal of comparative neurology.

[37]  Joseph S. Beckman,et al.  Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease , 1997, The Journal of Neuroscience.

[38]  P. Cras,et al.  Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease , 2004, Acta Neuropathologica.

[39]  John S. Kauer,et al.  Pathological changes in olfactory neurons in patients with Alzheimer's disease , 1989, Nature.

[40]  L. Maillard,et al.  Action des acides amines sur les sucres : formation des melanoidines par voie methodique , 1912 .

[41]  A. Cerami,et al.  High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Beal,et al.  Oxidative damage in Alzheimer's , 1996, Nature.

[43]  Mark A. Smith,et al.  Carbonyl‐Related Posttranslational Modification of Neurofilament Protein in the Neurofibrillary Pathology of Alzheimer's Disease , 1995, Journal of neurochemistry.

[44]  C. Bouras,et al.  Age-dependent accumulation of advanced glycosylation end products in human neurons , 1995, Neurobiology of Aging.

[45]  C. Harrington,et al.  Alzheimer's disease. A glycation connection. , 1994, Nature.

[46]  G. Perry,et al.  Neuronal Oxidative Stress Precedes Amyloid‐β Deposition in Down Syndrome , 2000 .

[47]  G. Perry,et al.  Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. , 2000, Journal of neuropathology and experimental neurology.

[48]  G. Perry,et al.  Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients , 2004, Aging cell.